Updated on 5 August 2026
In vivo Pharmacology
Discovery Services Consultant at Sygnature Discovery
Nottingham, United Kingdom
About
Sygnature Discovery supports projects at all drug discovery phases by delivering high-quality in vivo pharmacology data that drive confident decision making for our customers.
Our team of >60 in vivo scientist has deep expertise with a critical mass of projects and a proven track record in delivering validated models and impactful results across key therapeutic areas.
Our in vivo platform offers a full spectrum of solutions, including pharmacokinetics, target engagement and biomarkers, disease-relevant translational models, and exploratory toxicology. Continuous investment in advanced technologies enhance data translatability, improves project outcomes and maximize clinical relevance.
Each study is executed on time, with high quality and in full alignment with the highest standard of animal welfare.
-
CNS/Pain Models
-
Metabolic Disease Models
-
Inflammation & Immunology Models
-
Oncology Models
-
Non-Regulatory Toxicology
-
In Vivo Pharmacokinetics
-
Ex vivo Tissue Analysis
Type
- Research & Development
Organisation
Similar opportunities
Product
ORGANoro - A cardiac organoid based platform for drug screening and personalized medicine
- Buyer
- License partner
- Demonstration / Pilot projects
Beatrice Bassetti
Head Technology Transfer Office at Centro Cardiologico Monzino IRCCS
Milano, Italy
Service
Protein Science & Structural Biology
- Research & Development
Gaetano Cuciniello
Discovery Services Consultant at Sygnature Discovery
Nottingham, United Kingdom
Partnership
NIFT- First in class NEDD4 Inhibitors For cancer Therapy
- Other
- Joint development
- Technology transfer
Alessia Romussi
Intellectual Property Manager at IFOM ETS - the AIRC Institute of Molecular Oncology
Milano, Italy